U.S. markets closed

Outset Medical, Inc. (OM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.33+2.73 (+4.91%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close55.60
Open57.00
Bid58.28 x 1800
Ask60.56 x 900
Day's Range54.21 - 61.00
52 Week Range42.50 - 66.96
Volume5,247,991
Avg. Volume365,983
Market Cap2.497B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Outset Medical Prices Equity Offering At $53.50 Per Share
      Benzinga

      Outset Medical Prices Equity Offering At $53.50 Per Share

      View more earnings on OMSee more from BenzingaClick here for options trades from BenzingaJ&J Seeks To Conduct Study For COVID-19 Vaccine In India: ReutersHealthEquity Scoops Up Further For 0M© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Outset Medical Named a Winner in Round 2 of the KidneyX COVID-19 Kidney Care Challenge
      Business Wire

      Outset Medical Named a Winner in Round 2 of the KidneyX COVID-19 Kidney Care Challenge

      The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) have named Outset Medical’s Tablo Hemodialysis System® one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge, recognizing innovative solutions for safely delivering kidney care during the pandemic. Specifically designed to simplify dialysis treatment for patients and providers, Tablo is a first-of-its-kind enterprise solution that lowers the cost and complexity of dialysis and is approved for use across the entire continuum of care.

    • Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering
      Business Wire

      Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering

      Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 2,500,000 shares of its common stock sold by Outset and 3,444,859 shares of its common stock by certain of its stockholders at a public offering price of $53.50 per share. In addition, Outset and such selling stockholders granted the underwriters a 30-day option to purchase up to an additional 891,728 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The underwriting discounts and commissions will be borne by Outset with respect to the shares it sells in the offering and by the selling stockholders with respect to the shares they sell in the offering. The offering is expected to close on April 13, 2021, subject to the satisfaction of customary closing conditions.